Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01564654 · ClinicalTrials.gov registry record

A Retrospective Study of the iTotal CR Knee Replacement System

A clinical trial of Osteoarthritis, sponsored by Restor3D.

Completed
Registry status
89
Enrollment target
4
Study locations

NCT01564654 is a study of Osteoarthritis that has completed, run by Restor3D. The registered enrollment target is 89 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01564654, a study of Osteoarthritis, has completed, sponsored by Restor3D.

COMPLETED
Registry status
89 participants
Enrollment target
4
Study locations

Study Summary

This study involves retrospective collection of data regarding the first approximately 100 iTotal Knee Replacement System surgeries and their short term outcomes at a small set of centers throughout the US.

Conditions Studied

Interventions

  • DEVICE iTotal KRS

Study Locations (4)

California

  • STAR Orthopedics - La Quinta

Florida

  • Preferred Orthopedics of the Palm Beaches - Boynton Beach

Tennessee

  • Tennessee Orthopaedic Alliance - Nashville

Utah

  • Central Utah Clinic - Provo

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2012-01
Est. Completion 2013-01

Sponsor

Restor3D

20 total trials

What the Registry Record Tells You About NCT01564654

The ClinicalTrials.gov registry entry for NCT01564654 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (89% lower). The listed sponsor is Restor3D, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which iTotal KRS is the first listed.

NCT01564654 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT01564654 about?

NCT01564654 is a clinical study titled "A Retrospective Study of the iTotal CR Knee Replacement System". This study involves retrospective collection of data regarding the first approximately 100 iTotal Knee Replacement System surgeries and their short term outcomes at a small set of centers throughout the US.

What is the current status of trial NCT01564654?

This trial is currently completed. The enrollment target is 89 participants. The study started on 2012-01. Estimated completion is 2013-01.

What conditions does trial NCT01564654 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT01564654?

The interventions under investigation include: iTotal KRS (DEVICE).

Who is sponsoring clinical trial NCT01564654?

This trial is sponsored by Restor3D, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01564654 being conducted?

This trial has 4 study locations across California, Florida, Tennessee, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.